NCT05347225View on ClinicalTrials.gov

A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 9, 2022

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Hematological Malignancies
Interventions
DRUG

Nemtabrutinib

Nemtabrutinib tablets will be administered orally QD.

Trial Locations (5)

301636

Institute of hematology&blood disease hospital-Hematology ( Site 1001), Tianjin

410013

Hunan Cancer Hospital ( Site 1004), Changsha

450008

Henan Cancer Hospital-hematology department ( Site 1003), Zhengzhou

510080

Guangdong Provincial People's Hospital-hematology department ( Site 1002), Guangzhou

511400

SUN YAT-SEN UNIVERSITY CANCER CENTRE-Internal medicine ( Site 1007), Guangzhou

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY